Online inquiry

IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ445MR)

This product GTTS-WQ445MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRA gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001347829.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ445MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14633MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ12245MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ11826MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ10378MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ8197MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ1346MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ4552MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ11173MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW